sleven, that's what this letter from DRL to judge is about, am I wrong? So eventually we'll get to see the unredacted minutes of the meeting with DRL vs AMRN re the Sherman Act which is that AMRN cornered the mkt in API so no availability to generics. It's a frivolous lawsuit...look who leads the sales in GV.
Honorable Zahid N. Quraishi, U.S.D.J.
U.S. District Court for the District of New Jersey
Clarkson S. Fisher Federal Building
402 East State Street
Trenton, NJ 08608
Re: Dr. Reddy’s Laboratories Inc. v. Amarin Pharma, Inc., et al No. 21-10309 (ZNQ)(RLS)
Dear Judge Quraishi:
This firm, together with Wilson Sonsini Goodrich & Rosati P.C., represents Plaintiff Dr.
Reddy’s Laboratories Inc. (“DRL”) in the above-captioned litigation. We write to inform the
Court that DRL has reviewed the transcript of the oral argument held on September 27, 2022 and
that DRL has no redactions and does not object to unsealing the transcript. We have also been
informed by counsel for defendant Amarin Pharma Inc. and plaintiffs in the Direct Purchaser and
Indirect Purchaser cases (docket nos. 21-12747 and 21-12061) that those parties also have no
redactions.
Thank you for giving us the opportunity to review the transcript.
Respectfully Submitted,
s/ Frank D. Rodriguez
Frank D. Rodriguez
windelsmarx.com
SO ORDERED:
s/ Zahid N. Quraishi, U.S.D.J.
Dated: 10/14/2022
Market Data 
Markets 
